Key Highlights

  • Liminatus Pharma amended its InnocsAI merger to close ahead of shareholder approval, issuing 1.6 billion shares in common and convertible preferred stock.
  • The transaction allocates an aggregate of 11,188,729 common shares and 158,881.1271 Series A Preferred shares to former InnocsAI members, staying below Nasdaq’s ownership threshold.
  • Series A Preferred Stock converts into 10,000 common shares per preferred share, subject to future shareholder approval.
  • A two-year non-compete agreement binds InnocsAI’s key personnel post-merger, protecting Liminatus Pharma’s competitive edge.

Merger Restructuring Announced

Liminatus Pharma has revised its pending acquisition of InnocsAI, replacing the original Merger Agreement dated as of May 17, 2026 with terms intended to streamline the closing process. The updated structure removes the requirement for immediate shareholder approval, prioritizing the rapid integration of InnocsAI’s artificial intelligence-driven drug discovery platform. This adjustment reflects the company’s effort to navigate regulatory requirements while addressing operational timelines in a competitive sector.

Stock Issuance Breakdown

The amended terms call for Liminatus Pharma to issue 1.6 billion shares as consideration for the merger, divided between common stock and a newly established class of preferred shares. The allocation includes an aggregate of 11,188,729 common shares and 158,881.1271 Series A Preferred shares to the former members of InnocsAI. This distribution ensures compliance with Nasdaq listing rules, which cap significant ownership changes at an estimated 19.99%.

By structuring the deal in this manner, Liminatus Pharma avoids triggering a shareholder vote while maintaining the transaction’s financial terms.

Preferred Stock Mechanics

The Series A Preferred Stock is designed without voting rights but includes a conversion feature allowing holders to exchange each preferred share for 10,000 common shares at their discretion. Conversion remains dependent on future shareholder approval, aligning with Nasdaq’s regulatory framework. The preferred shares hold equal standing with common stock regarding dividends and liquidation preferences, providing a measure of protection against dilution while deferring the full impact on existing shareholders.

Liminatus Pharma’s amended certificate of incorporation authorizes the company to issue 1,000,000 shares of preferred stock, with a par value of $0.0001 per share, and has designated 160,000 shares for this series.

Registration and Non-Compete Terms

The deal also incorporates a Non-Compete Agreement, which restricts key InnocsAI personnel from engaging in competing activities for two years post-merger. These provisions are outlined in Exhibits 10.1 and 10.2 of the agreement and aim to protect the combined entity’s intellectual property and workforce stability, critical factors in the fast-evolving AI-driven biotech landscape.

Regulatory and Capital Considerations

The transaction leverages a Section 4(a)(2) exemption under the Securities Act of 1933, allowing Liminatus Pharma to issue shares without public registration initially. The company’s leadership has emphasized the need for additional capital to support ongoing research and development programs, positioning the merger as a strategic move to enhance its long-term growth trajectory. Industry observers note that the deal’s structure helps mitigate short-term dilution risks while enabling scalable drug development, a key advantage in a sector where computational tools are increasingly driving innovation.

Timeline and Next Steps

Closing the merger remains subject to standard conditions, with Liminatus Pharma planning a future shareholder vote to approve the conversion of the Series A Preferred Stock. The company filed the Certificate of Designation for the preferred shares with the state of Delaware on July 2, 2026, formalizing its terms. Stakeholders are closely monitoring the integration timeline, particularly its implications for Liminatus Pharma’s financial runway and the acceleration of its drug discovery pipeline.

Market and Sector Impact

The revised terms underscore Liminatus Pharma’s urgency to deploy InnocsAI’s technology amid growing competition in AI-powered drug discovery. The biotech industry has witnessed a rise in mergers and acquisitions as companies seek to strengthen their pipelines with advanced computational platforms. The deal’s structure, balancing speed with regulatory compliance, could serve as a model for similar transactions, especially for Nasdaq-listed firms navigating shareholder approval thresholds.

As the sector continues to evolve, such strategic moves may become increasingly common in efforts to secure a competitive edge.

FAQs

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.